Key result
Sirtuins show preclinical promise for predicting and treating AMI but human clinical data remains scarce.
Why the study?
Early diagnosis of acute myocardial infarction remains challenging, and while preclinical studies of sirtuins as predictive agents or complementary treatments are promising, human clinical data are scarce.
What is the predictive value of sirtuins in the early detection and management of acute myocardial infarction?
What is the predictive value of sirtuins in the early detection and management of acute myocardial infarction?
While preclinical data suggest sirtuins may serve as novel predictive biomarkers or therapeutic targets in acute myocardial infarction, clinical evidence remains limited.
Scarce human data preclude sirtuin use in AMI; leaves open translation of preclinical promise via prospective trials.
Acute myocardial infarction (AMI) is a non-transmissible condition with high prevalence, morbidity, and mortality. Different strategies for the management of AMI are employed worldwide, but its early diagnosis remains a major challenge. Many molecules have been proposed in recent years as predictive agents in the early detection of AMI, including troponin (C, T, and I), creatine kinase MB isoenzyme, myoglobin, heart-type fatty acid-binding protein, and a family of histone deacetylases with enzymatic activities named sirtuins. Sirtuins may be used as predictive or complementary treatment strategies and the results of recent preclinical studies are promising. However, human clinical trials and data are scarce, and many issues have been raised regarding the predictive values of sirtuins. The present review summarizes research on the predictive value of sirtuins in AMI. We also briefly summarize relevant clinical trials and discuss future perspectives and possible clinical applications.
No takes yet. Share an insight, caveat, or question.
Gasparotto et al. (2020) conducted a review in Acute myocardial infarction (AMI). Sirtuins was evaluated. Sirtuins show promise as predictive agents and complementary treatment strategies for acute myocardial infarction in preclinical studies, but human clinical trials and data remain scarce.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: